...Joško Osredkar; Kiran Kumar Jagarlamudi; Diana Cviič; Erik Škof; Branko Cvjetićanin; Andrej Zore; David Lukanović; Staffan Eriksson; Leon Meglič Introduction: Ovarian cancer is the eighth most common cause of cancer death in women. One of the major concerns is almost two-thirds of cases...

... strategies among international experts in peritoneal carcinosis, specifically their decision-making in the process of patient selection for hyperthermic intraperitoneal chemotherapy (HIPEC) in women suffering from ovarian cancer, to identify relevant decision-making criteria, and to quantify the level...

.... Patients affected by ovarian cancer (OC) often experience a chronicization and slow progression of their disease, and chemotherapy is proposed until the end of life. Methods: We retrospectively analyzed data from patients affected by OC treated at our department and having died in the period between 2007...

...Maurie Markman Based on the results of several phase 3 randomized trials, “maintenance therapy” (prolonged treatment after an initial response to cytotoxic chemotherapy) has assumed a critical role in the routine care of advanced epithelial ovarian cancer. While earlier data had provided support...

...Heidi Kemiläinen; Kaisa Huhtinen; Annika Auranen; Olli Carpén; Leena Strauss; Matti Poutanen Objective: The aim of this study was to characterize the expression of hydroxysteroid (17β) dehydrogenase type 12 (HSD17B12), an enzyme involved in the synthesis of arachidonic acid (AA), in ovarian cancer...

... every 10 days as a single agent in recurrent ovarian cancer after 3 prior regimens. Method: Trabectedin 0.6 mg/m 2 was administered as a 3-h infusion every 10 days on a 21-day cycle. The study population was compared to patients treated with weekly paclitaxel 80 mg/m 2 intravenously on days 1, 8, 15...

... been made in order to increase life expectancy in ovarian cancer (OC) patients. However, just a few studies have investigated the impact of OC on quality of life (QoL) and sexual function in OC cases during treatment. Objective: The aim of this study was to evaluate the QoL and sexual function of OC...

...Phamela Ferreira Klimczak; Danielle Hornung Ventury; Fabio Rueda Faucz; Nikolaos Settas; Cleber Machado de Souza; Vanessa Santos Sotomaior Ovarian cancer (OC) is the eighth most common cancer among women in Brazil and seventh in the world population. OC has a high mortality rate and is difficult...

...Aminah Jatoi; Robert A. Vierkant; Kieran M. Hawthorne; Matthew S. Block; Susan J. Ramus; Nicholas B. Larson; Brooke L. Fridley; Ellen L. Goode Objective: Ovarian cancer is the most lethal gynecological malignancy, but information relevant to prognosis and outcomes remain unknown. Here, we used...

...Aminah Jatoi; Carmen Radecki Breitkopf; Nathan R. Foster; Matthew S. Block; Megan Grudem; Andrea Wahner Hendrickson; Rachel E. Carlson; Brigitte Barrette; Nina Karlin; Alan P. Fields Purpose: This trial was undertaken (1) to determine the feasibility of enrolling asymptomatic ovarian cancer...

...) in patients undergoing optimal primary surgical cytoreduction (RT <1 cm) and to identify the prognostic significance of postoperative CT scan of RT. Methods: Patients with FIGO stage III-IV ovarian cancer treated at the Gynecologic Oncology Unit of the National Cancer Institute between November 2011...

... as a treatment of human ovarian cancer, we tested nilotinib's preclinical activity in ovarian cancer cell lines with different tyrosine kinase expression patterns. Methods: The effects of nilotinib on ovarian cancer cell growth were studied alone and in combination with carboplatin and paclitaxel. Proapoptotic...

...Shizuo Machida; Yuji Takei; Chikako Yoshida; Yoshifumi Takahashi; Takahiro Koyanagi; Naoto Sato; Akiyo Taneichi; Yasushi Saga; Hiroyuki Fujiwara; Mitsuaki Suzuki Objectives: While radiation therapy is administered as a palliative treatment for recurrent ovarian cancer, it remains unclear whether...

...D. Lorusso; F. Cirillo; M. Mancini; G.B. Spatti; B. Grijuela; A. Ditto; F. Raspagliesi Objectives: The objective of this study was to examine whether the oncologic outcomes of BRCA1 -associated and BRCA2 -associated ovarian cancers correlate differently. Methods: Genetic data and clinical...

...Sabrina Mathey; Monika Karla Graeser; Christine zu Eulenburg; Linn Woelber; Fabian Trillsch; Fritz Jaenicke; Volkmar Müller; Karin Milde-Langosch; Sven Mahner Objectives: Angiogenesis plays an important role in ovarian cancer. The interaction of platelet-derived growth factor receptor-beta (PDGFR-β...

... to platinum or taxanes has improved the prognosis of platinum-resistant patients. Survival of patients with ovarian cancer is generally improving [ 1 ]. This improvement is most probably multifactorial [ 2 ], mainly reflecting progress in the available therapeutic modalities, i.e. primary debulking surgery...

...Flora Zagouri; Theodoros N. Sergentanis; Dimosthenis Chrysikos; Martin Filipits; Rupert Bartsch Objective: Ovarian cancer in pregnancy is uncommon; however, this diagnosis adds complexity to cancer treatment recommendations. This is the first systematic review to synthesize all available data...

... not due to ovarian cancer progression. For this analysis, survival time was calculated from treatment until death from ovarian cancer (focal event) or until death from any other cause (censored) or until last follow-up for alive women (censored). Survival curves were produced with the Kaplan-Meier method...

...M. Bruzzone; M.G. Centurioni; P. Giglione; M. Gualco; D.F. Merlo; L. Miglietta; M. Cosso; F. Giannelli; P. Cristoforoni; M. Ferrarini Objective: The outcome of advanced ovarian cancer patients has not significantly improved since the introduction of platinum. One of the major reasons...

...Dirk O. Bauerschlag; Ole Ammerpohl; Karen Bräutigam; Christian Schem; Qiong Lin; Marion T. Weigel; Felix Hilpert; Norbert Arnold; Nicolai Maass; Ivo Meinhold-Heerlein; Wolfgang Wagner Objective: Many patients with ovarian cancer disease relapse within 6 months after adjuvant chemotherapy...